US › Healthcare

Instil Bio Inc. (TIL)

US · Healthcare · Biotechnology

$7.25+0.42%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-4.2M
Profit YoY
+85.1%
EPS
$-0.62
EPS estimate
$-0.59

EPS came in at -0.62 against a street estimate of -0.59 — a miss of 5.1%.

Key statistics

Market cap
$48.3M
Forward P/E
0.0
P/B
0.44
Book value
$16.32
EPS (TTM)
$-7.00
52-week high
$33.83
52-week low
$5.67
50-day MA
$7.70
200-day MA
$9.67
Beta
1.91

Analyst view

Analysts rate Instil Bio Inc. a buy (3 buy, 1 hold, 0 sell out of 4) with an average price target of $7.00.

Shareholding

Insiders
6.56%
Institutions
62.09%

Largest institutional holders

FundStake
BML Capital Management LLC9.52%
Cpmg Inc6.06%
Kalehua Capital Management LLC4.76%
Vivo Capital, LLC4.32%
Vanguard Capital Management, LLC2.57%
Millennium Management LLC1.96%
Renaissance Technologies Corp0.87%
BlackRock Inc0.77%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Instil Bio Inc. — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.